Eric Bjerkholt is the CEO of Surrozen, Inc., currently leading the company as it advances in biotechnology. With a solid background in finance and corporate development, Eric has served in key roles in several biotech firms, including Chinook Therapeutics and...

Eric Bjerkholt is the CEO of Surrozen, Inc., currently leading the company as it advances in biotechnology. With a solid background in finance and corporate development, Eric has served in key roles in several biotech firms, including Chinook Therapeutics and Aimmune Therapeutics, where he successfully oversaw a major acquisition by Nestlé for $2.6 billion. His educational credentials include an MBA from Harvard Business School and a degree from the University of Oslo in Norway. In 2023, he joined Surrozen's board of directors as a Class I director, bringing extensive leadership experience to the team. His leadership style focuses on aligning performance with corporate goals, which is evident in his recent compensation structure where he earned $825,320 in total, a part of which was tied to corporate performance goals. Eric is known for fostering strategic growth and maintaining strong financial practices in the organizations he leads. His prior experience includes over a decade at Sunesis Pharmaceuticals and various senior positions in investment banking, which strengthens his ability to guide Surrozen in a competitive landscape. He's also an active board member at several other biotech firms, further illustrating his commitment to the industry.